Zacks Investment Research lowered shares of HMS (NASDAQ:HMSY) from a hold rating to a sell rating in a research report released on Saturday, February 17th.
According to Zacks, “HMS Holdings Corp. is a leading provider of cost containment solutions in the U.S. healthcare marketplace. Using innovative technology as well as extensive data services and powerful analytics, the Company delivers coordination of benefits, payment integrity, and health management and member engagement solutions to help customers recover improper payments; prevent future improper payments; reduce fraud, waste and abuse; effectively engage their members and better manage the care they receive; and ensure regulatory compliance. The Company serves commercial health plans, state government agencies, federal programs, at-risk providers, pharmacy benefit managers and employers. “
Other analysts have also issued research reports about the company. Robert W. Baird reissued a buy rating on shares of HMS in a report on Sunday, November 19th. Canaccord Genuity decreased their price objective on HMS from $22.00 to $17.00 and set a buy rating on the stock in a research note on Monday, November 6th. Cantor Fitzgerald reiterated a hold rating and set a $16.00 target price on shares of HMS in a research report on Sunday, November 19th. BidaskClub upgraded HMS from a sell rating to a hold rating in a research report on Wednesday, December 6th. Finally, Citigroup assumed coverage on HMS in a research report on Thursday, January 4th. They set a neutral rating on the stock. Three analysts have rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $20.50.
HMS (NASDAQ:HMSY) last released its quarterly earnings data on Friday, February 23rd. The business services provider reported $0.15 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.07). The business had revenue of $148.49 million during the quarter, compared to analysts’ expectations of $136.77 million. HMS had a return on equity of 7.33% and a net margin of 7.56%. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS. sell-side analysts expect that HMS will post 0.65 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of HMSY. FMR LLC acquired a new position in shares of HMS in the 2nd quarter worth approximately $3,617,000. Parametric Portfolio Associates LLC boosted its position in HMS by 15.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 152,580 shares of the business services provider’s stock valued at $2,823,000 after purchasing an additional 20,802 shares during the period. Voya Investment Management LLC boosted its position in HMS by 7.3% during the 2nd quarter. Voya Investment Management LLC now owns 39,092 shares of the business services provider’s stock valued at $723,000 after purchasing an additional 2,676 shares during the period. State Street Corp boosted its position in HMS by 4.4% during the 2nd quarter. State Street Corp now owns 2,217,293 shares of the business services provider’s stock valued at $41,018,000 after purchasing an additional 92,900 shares during the period. Finally, Bank of Nova Scotia boosted its position in HMS by 5.5% during the 2nd quarter. Bank of Nova Scotia now owns 41,635 shares of the business services provider’s stock valued at $770,000 after purchasing an additional 2,160 shares during the period. Institutional investors own 99.40% of the company’s stock.
HMS Holdings Corp. is a holding company. The Company, through its subsidiaries, operates in the United States healthcare insurance benefit cost containment marketplace. It provides coordination of benefits services to government, and private healthcare payers and sponsors. Its payment integrity services ensure that healthcare claims billed are accurate and appropriate.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HMS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HMS and related companies with MarketBeat.com's FREE daily email newsletter.